BTIG Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $34
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsInitiationPrice Target
BTIG analyst Kambiz Yazdi initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $34.
BTIG analyst Kambiz Yazdi initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $34.